公开(公告)号：EP1888582A1

公开(公告)日：2008-02-20

申请号：EP06784721.0

申请日：2006-06-08

申请人： Bristol-Myers Squibb Company

发明人： LI, James J. ,  HAMANN, Lawrence G. ,  WANG, Haixia ,  RUAN, Zheming ,  COOPER, Christopher B. ,  LI, Jun ,  ROBL, Jeffrey A.

IPC分类号： C07D471/04 ,  A61K31/435 ,  A61P3/00

CPC分类号： C07D471/04

摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure:(I) or stereoisomers or pharmaceutically acceptable salts thereof, wherein W, L, R3, R3a, R3b and R4 are defined herein.

公开(公告)号：EP2702042A1

公开(公告)日：2014-03-05

申请号：EP12723982.0

申请日：2012-04-27

申请人： Bristol-Myers Squibb Company

发明人： ROBL, Jeffrey A. ,  LI, Jun ,  KENNEDY, Lawrence J. ,  WALKER, Steven J. ,  WANG, Haixia ,  WASHBURN, William N. ,  AHMAD, Saleem ,  NGU, Khehyong

IPC分类号： C07D215/08 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04 ,  C07D417/04 ,  A61K31/4709 ,  A61K31/553 ,  A61K31/554 ,  A61P3/00 ,  A61P9/00 ,  C07D401/14 ,  C07D413/14

CPC分类号： C07D401/04 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/4747 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  A61K31/675 ,  A61K45/06 ,  C07D215/08 ,  C07D221/16 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07F9/60

摘要： Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R
3 , R
4 , R
4a , R
5a , R
5b , R
5c , R
5d , R
5e , R
6a , R
6b , and R
6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

公开(公告)号：EP2566862A1

公开(公告)日：2013-03-13

申请号：EP11720257.2

申请日：2011-05-04

申请人： Bristol-Myers Squibb Company

发明人： YE, Xiang-Yang ,  WACKER, Dean A. ,  ROBL, Jeffrey A.

IPC分类号： C07D405/14 ,  A61K31/506 ,  A61P5/50

CPC分类号： C07D405/14

摘要： Novel compounds of structure Formula I: or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein A, L, m, n, o, p, R
2, R
3 , R
3 , R
4 and R
5 are defined herein, are provided which are GPR1 19 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

公开(公告)号：EP2566860A1

公开(公告)日：2013-03-13

申请号：EP11720256.4

申请日：2011-05-04

申请人： Bristol-Myers Squibb Company

发明人： YE, Xiang-Yang ,  WACKER, Dean A. ,  ROBL, Jeffrey A. ,  WANG, Ying

IPC分类号： C07D401/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  A61K31/506 ,  A61K31/4545 ,  A61K31/437 ,  A61K31/5375 ,  A61K31/496 ,  A61P3/10 ,  A61P3/04

CPC分类号： C07D417/14 ,  C07D401/14 ,  C07D413/14 ,  C07D417/12

摘要： Novel compounds of structure Formula I: or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein A, D, Di, E, J, L, n, Q, R
2 and R
4 are defined herein, are provided which are GPR119 G protein- coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

公开(公告)号：EP2054368A2

公开(公告)日：2009-05-06

申请号：EP07814376.5

申请日：2007-08-23

申请人： Bristol-Myers Squibb Company

发明人： YE, Xiang-yang ,  ROBL, Jeffrey A. ,  HANSON, Ronald L. ,  GUO, Zhiwei ,  PATEL, Ramesh N.

IPC分类号： C07C61/39 ,  C07C61/40 ,  C07D203/18 ,  C07D205/04 ,  C07D205/08 ,  C07D263/04 ,  C07D263/30 ,  C07D317/72 ,  C07D493/08 ,  C07D295/18 ,  C07C62/38 ,  C07D451/02 ,  C07C57/00 ,  C07C59/00

CPC分类号： C07C61/40 ,  C07B2200/07 ,  C07C57/50 ,  C07C57/62 ,  C07C59/54 ,  C07C59/56 ,  C07C59/72 ,  C07C59/88 ,  C07C61/39 ,  C07C62/38 ,  C07C2603/66 ,  C07C2603/74 ,  C07D203/18 ,  C07D205/04 ,  C07D205/06 ,  C07D207/12 ,  C07D207/14 ,  C07D207/16 ,  C07D211/42 ,  C07D211/46 ,  C07D213/40 ,  C07D217/02 ,  C07D241/08 ,  C07D257/04 ,  C07D261/02 ,  C07D261/08 ,  C07D263/04 ,  C07D277/04 ,  C07D277/46 ,  C07D277/64 ,  C07D277/82 ,  C07D285/135 ,  C07D295/185 ,  C07D295/205 ,  C07D401/12 ,  C07D403/04 ,  C07D407/06 ,  C07D413/04 ,  C07D471/04 ,  C07D493/08

摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: enantiomers, diastereomers, solvates, or salts thereof, wherein A, W, X and Z are defined herein.

摘要翻译： 提供了新的化合物，它是11-β-羟基类固醇脱氢酶I型抑制剂。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病进展。 这些新化合物具有以下结构：其中A，W，X和Z如本文所定义，其对映异构体，非对映异构体，溶剂合物或其盐。

公开(公告)号：EP1989190A2

公开(公告)日：2008-11-12

申请号：EP07757668.4

申请日：2007-03-01

申请人： Bristol-Myers Squibb Company

发明人： LI, Jun ,  ROBL, Jeffrey A. ,  KENNEDY, Lawrence J.

IPC分类号： C07D253/06

CPC分类号： C07D253/10 ,  C07D253/07

摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein.

公开(公告)号：EP2566862B1

公开(公告)日：2015-09-16

申请号：EP11720257.2

申请日：2011-05-04

申请人： Bristol-Myers Squibb Company

发明人： YE, Xiang-Yang ,  WACKER, Dean A. ,  ROBL, Jeffrey A.

IPC分类号： C07D405/14 ,  A61K31/506 ,  A61P5/50

CPC分类号： C07D405/14

公开(公告)号：EP1989190B1

公开(公告)日：2011-04-27

申请号：EP07757668.4

申请日：2007-03-01

申请人： Bristol-Myers Squibb Company

发明人： LI, Jun ,  ROBL, Jeffrey A. ,  KENNEDY, Lawrence J.

IPC分类号： C07D253/06

CPC分类号： C07D253/10 ,  C07D253/07

摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein.

公开(公告)号：EP1888582B1

公开(公告)日：2010-11-10

申请号：EP06784721.0

申请日：2006-06-08

申请人： Bristol-Myers Squibb Company

发明人： LI, James J. ,  HAMANN, Lawrence G. ,  WANG, Haixia ,  RUAN, Zheming ,  COOPER, Christopher B. ,  LI, Jun ,  ROBL, Jeffrey A.

IPC分类号： C07D471/04 ,  A61K31/435 ,  A61P3/00

CPC分类号： C07D471/04

摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure:(I) or stereoisomers or pharmaceutically acceptable salts thereof, wherein W, L, R3, R3a, R3b and R4 are defined herein.

公开(公告)号：EP2046753A2

公开(公告)日：2009-04-15

申请号：EP07812540.8

申请日：2007-07-02

申请人： Bristol-Myers Squibb Company

发明人： ROBL, Jeffrey A. ,  WU, Shung C. ,  YOON, David S.

IPC分类号： C07D217/24 ,  C07D221/04 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D453/00 ,  C07D471/04 ,  A61K31/4355 ,  A61P3/00

CPC分类号： C07D217/24 ,  C07D221/04 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D453/00 ,  C07D471/04

摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure formula (I) enantiomers, diastereomers, solvates, salts, tautomers or prodrugs thereof wherein, A, W, X, Y and R1 are defined herein.